Hi Madly. This was also out today.
Business Editors and Health/Medical Writers
BIOWIRE2K
LA JOLLA, Calif.--(BW HealthWire)--Feb. 15, 2000--La Jolla
Diagnostics Inc. (OTC BB: LAJD), Tuesday announced that it has added
several new distributors and independent reps for its line of health care
products.
Together, these new distributors will represent the Company's products
to over 1,000 locations, including pharmacies, health food stores and the
offices of physicians, chiropractors, and other health care providers.
"We are receiving extremely positive feedback from both consumers and
health care professionals, especially regarding our newly reformulated
MigraSpray," said Don Brucker, CEO. "In the last month we have
witnessed a dramatic rise in the number of distributors interested in handling
our product line, and we appear to be on track to make our goal of having
distribution in every state by year end."
MigraSpray is a nutraceutical product containing the herb feverfew,
which has been used for centuries as a natural headache remedy. Clinical
studies published in both Lancet and the British Medical Journal have
supported the effectiveness of feverfew use in migraine patients.
The Company believes that MigraSpray, which is designed to be
sprayed under the tongue before swallowing, is substantially faster acting
and effective than commonly available feverfew capsules. "We firmly
believe that MigraSpray is the best product of its type in the world," said
Stephen Roberts, MD, President. "Americans spend over $8 billion per
year on various products to relieve headaches, but the old version of
MigraSpray required refrigeration, which proved to be a major impediment
to sales. The reformulated MigraSpray does not require any special
handling. As such, a number of E-commerce sites and traditional retailers
are now pursuing distribution with us."
La Jolla Diagnostics is an emerging company engaged in the
development and marketing of health care products, dietary supplements,
and through its subsidiary DiagnosTech Inc., state-of-the-art rapid
diagnostic tests including a unique proprietary test for active Tuberculosis.
Forward-looking statements in this release are made pursuant to the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Investors are cautioned that such forward-looking statements involve
risk and uncertainties.
--30--KM/np* JS/np
CONTACT: La Jolla Diagnostics Inc., La Jolla
Don Brucker, C.E.O.
Phone: 800/454-6790
Fax: 619/454-7851
lajd.com
e-mail: lajd96@aol.com
KEYWORD: CALIFORNIA
INDUS |
